ARTICLE | Clinical News
Kineret: Ph II anaGO started
January 12, 2017 10:14 PM UTC
Swedish Orphan Biovitrum began the double-blind, placebo-controlled, North American Phase II anaGO trial to compare 100 and 200 mg subcutaneous Kineret once daily for 5 days plus intramuscular triamci...
BCIQ Target Profiles